Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies

Peer Review reports

Original Submission
8 Mar 2019	Submitted	Original manuscript
28 Sep 2019	Reviewed	Reviewer Report - Manuela Schmidinger
12 Dec 2019	Reviewed	Reviewer Report - Reviewer 2
27 Jan 2020	Author responded	Author comments - Xinan Sheng
22 Feb 2020	Reviewed	Reviewer Report - Manuela Schmidinger
28 Feb 2020	Author responded	Author comments - Xinan Sheng
Resubmission - Version 2
27 Jan 2020	Submitted	Manuscript version 2
Publishing
3 Mar 2020	Editorially accepted
14 Mar 2020	Article published	10.1186/s12885-020-6708-8

Back to article page